[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX359209B - Terapia de combinacion de procaspasa para gliobastoma. - Google Patents

Terapia de combinacion de procaspasa para gliobastoma.

Info

Publication number
MX359209B
MX359209B MX2014010714A MX2014010714A MX359209B MX 359209 B MX359209 B MX 359209B MX 2014010714 A MX2014010714 A MX 2014010714A MX 2014010714 A MX2014010714 A MX 2014010714A MX 359209 B MX359209 B MX 359209B
Authority
MX
Mexico
Prior art keywords
compounds
procaspase
glioblastoma
combination therapy
combinations
Prior art date
Application number
MX2014010714A
Other languages
English (en)
Other versions
MX2014010714A (es
Inventor
j hergenrother Paul
C Botham Rachel
M Fan Timothy
j gilbert Mark
K Handley Michael
M Tarasow Theodore
J Riggins Gregory
Joshi Avadhut
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2014010714A publication Critical patent/MX2014010714A/es
Publication of MX359209B publication Critical patent/MX359209B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona composiciones y métodos para la inducción de muerte celular, por ejemplo, muerte de células de cáncer. Las combinaciones de compuestos y métodos relacionados de uso son descritos, incluyendo el uso de compuestos en terapia para el tratamiento de cáncer e inducción selectiva de apoptosis en células. Las combinaciones de medicamentos descritas pueden tener menores efectos de neurotoxicidad que otros compuestos y combinaciones de compuestos.
MX2014010714A 2012-03-06 2013-03-06 Terapia de combinacion de procaspasa para gliobastoma. MX359209B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607103P 2012-03-06 2012-03-06
PCT/US2013/029391 WO2013134398A1 (en) 2012-03-06 2013-03-06 Procaspase combination therapy for glioblastoma

Publications (2)

Publication Number Publication Date
MX2014010714A MX2014010714A (es) 2015-03-10
MX359209B true MX359209B (es) 2018-09-19

Family

ID=49117298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010714A MX359209B (es) 2012-03-06 2013-03-06 Terapia de combinacion de procaspasa para gliobastoma.

Country Status (15)

Country Link
US (5) US9421202B2 (es)
EP (2) EP2822546B1 (es)
JP (2) JP6222608B2 (es)
KR (1) KR102075811B1 (es)
CN (1) CN104540501B (es)
AU (1) AU2013230985B2 (es)
BR (1) BR112014022123B1 (es)
CA (1) CA2866020C (es)
DK (2) DK2822546T3 (es)
ES (2) ES2738448T3 (es)
HK (1) HK1204985A1 (es)
IN (1) IN2014MN01944A (es)
MX (1) MX359209B (es)
RU (1) RU2636234C2 (es)
WO (1) WO2013134398A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
KR102656027B1 (ko) 2015-06-05 2024-04-08 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｐａｃ-1 조합 치료
KR101712638B1 (ko) 2015-08-19 2017-03-07 한국과학기술연구원 Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제
US11510919B2 (en) 2017-11-17 2022-11-29 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
AU2019354771A1 (en) 2018-10-05 2021-04-01 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
EP3934662A1 (en) * 2019-03-05 2022-01-12 Dow Global Technologies LLC Inducing caspase activity
CA3142157A1 (en) * 2019-05-30 2020-12-03 The Board Of Trustees Of The University Of Illinois Procaspase-3 activation and immunotherapy for treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
WO2000006750A2 (en) 1998-07-27 2000-02-10 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU2002241508A1 (en) 2000-11-20 2002-06-24 Lawrence C. Fritz Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2003024955A2 (en) 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
US20040180828A1 (en) 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
US7632972B2 (en) 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
US8440610B2 (en) * 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
CN101184491A (zh) * 2005-05-26 2008-05-21 伊利诺伊大学评议会 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
CA2611530C (en) 2005-06-23 2012-11-20 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI373473B (en) * 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
EP1940395A2 (en) * 2005-09-16 2008-07-09 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US7886969B2 (en) 2005-12-06 2011-02-15 Visa U.S.A. Inc. Method and system for loading and reloading portable consumer devices
EP2034828A4 (en) 2006-05-19 2011-04-06 Univ Illinois PHOSPHOROUS COMPOUNDS CONTAINING TRIPHENYLMETHYLPHOSPHONATE ESTERS FOR THE TREATMENT OF MELANOMA AND OTHER CANCERS
RU2360692C1 (ru) 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, стимулирующее апоптоз клеток лейкемии человека
CN101965189A (zh) 2008-01-11 2011-02-02 加利福尼亚大学董事会 处决胱冬酶原3、6和7的激活剂
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
CN106946812B (zh) 2009-02-09 2020-10-09 伊利诺伊大学评议会 作为个性化抗癌药的胱天蛋白酶原活化化合物的设计、合成和评价
TWI386203B (zh) * 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers

Also Published As

Publication number Publication date
ES2738448T3 (es) 2020-01-22
WO2013134398A1 (en) 2013-09-12
ES2646008T3 (es) 2017-12-11
CN104540501A (zh) 2015-04-22
IN2014MN01944A (es) 2015-07-10
US10874666B2 (en) 2020-12-29
US10085978B2 (en) 2018-10-02
JP2015509964A (ja) 2015-04-02
US20210290616A1 (en) 2021-09-23
US20190099419A1 (en) 2019-04-04
US20240082241A1 (en) 2024-03-14
KR102075811B1 (ko) 2020-02-10
JP2018052932A (ja) 2018-04-05
RU2014139955A (ru) 2016-04-27
CA2866020A1 (en) 2013-09-12
MX2014010714A (es) 2015-03-10
KR20140143771A (ko) 2014-12-17
AU2013230985B2 (en) 2016-05-12
US20150025083A1 (en) 2015-01-22
BR112014022123A2 (es) 2017-06-20
RU2636234C2 (ru) 2017-11-21
CA2866020C (en) 2020-09-22
EP2822546B1 (en) 2017-07-12
EP2822546A1 (en) 2015-01-14
US20170042886A1 (en) 2017-02-16
EP3290035A1 (en) 2018-03-07
BR112014022123B1 (pt) 2022-09-20
DK3290035T3 (da) 2019-08-05
DK2822546T3 (en) 2017-10-30
US9421202B2 (en) 2016-08-23
JP6222608B2 (ja) 2017-11-01
AU2013230985A1 (en) 2014-10-16
US11844798B2 (en) 2023-12-19
HK1204985A1 (en) 2015-12-11
EP2822546A4 (en) 2015-10-28
CN104540501B (zh) 2016-11-23
EP3290035B1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
MX2021001878A (es) Metodos y composiciones para mejorar las celulas t reguladoras cd4+.
GB201106750D0 (en) Novel compounds
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
GB201106743D0 (en) Novel compounds
EP2904106A4 (en) COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2014010714A (es) Terapia de combinacion de procaspasa para gliobastoma.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
TW201611843A (en) Methods of treatment with arginine deiminase
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2016016419A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2017015532A (es) Terapia de combinacion pac-1.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration